The treatment of kidney cancer has been re-energised by the introduction of novel therapeutics and innovative surgical advances. Edited and written by medical oncologists and surgeons, this new reference covers the full spectrum of renal cell carcinoma from screening, epidemiology, and pathology to molecular genetics, surgical management, and therapy of metastatic disease.
Front and centre is the biology of renal cell carcinoma, where researchers have made great progress in expanding our understanding of mechanisms and processes making therapeutic advances possible. This atlas includes the latest information on the immunobiology of kidney cancer as well as pathways involving vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR). The bulk of the chapters deal with the practical management of the continuum of kidney cancer ranging from the small renal mass, through locally advanced disease, to the metastatic patient.
Different treatment approaches are discussed within the context of each of these clinical scenarios, and surgical and therapeutic advances are highlighted. In addition, special populations such as patients requiring palliative care, those with brain or bone metastasis, and those with inherited renal cell carcinoma are discussed.
Up to date discussion of the newest data on targeted agents
Comprehensive analysis of all aspects of RCC management
Chapters of special clinical interests including Partial Nephrectomy, Angiogenesis Biology, and Rapamycin Inhibition
Extensive details on new research pathways in VEGF and mTOR
Extensive description of imaging techniques
Brian I. Rini, MD, Associate Professor Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, Associate Professor of Medicine Cleveland Clinic Foundation/ Case Western Reserve, University Lerner College of Medicine Cleveland, OH. Steven C. Campbell, MD, PhD Professor of Surgery, Section of Urological Oncology Glickman Urological Institute Cleveland Clinic Foundation Cleveland, OH.
Introduction - Rini/Campbell 1: Pathology - (Zhou, CCF) 2: Epidemiology and Screening of RCC (Godley) 3: Diagnosis and Management of Inherited RCC(Nathanson/Stephenson) 4: Genetics of Sporadic RCC (Bin Teh) 5: Imaging Techniques (Herts) 6: Management of Small Renal Masses a: Biopsy (Uzzo) b: Non-invasive Techniques (Matin) c: Partial Nephrectomy (Novick) 7: Prognostic Factors in Localized RCC (Pantuc, Belldegrun) 8: Radical Nephrectomy for Localized RCC (Samir Taneja - NYU) 9: Surgical Management of Locally-Advanced RCC (Wood) 10: Adjuvant Therapy in RCC (Eisen-Caimbridge) 11: Prognostic Factors in Metastatic RCC (Choueiri-CCF) 12: Immunobiology of Metastatic RCC (Jim Finke - CCF) 13: Immunotherapy in Metastatic RCC (David McDermott - BI) 14: Angiogenesis Biology in Metastatic RCC (Kim Rathmell - UNC) 15: Anti-VEGF Therapy in Metastatic RCC a: VEGF Ligand-binding Agents (Rini/Rathmell) b: Therapeutic Inhibition of VEGF Receptor (Oliver Rixe - France) 16: Akt Pathway Biology in Metastatic RCC (Dan George - Duke) 17: Therapeutic mTOR Inhibition in Metastatic RCC (Gary Hudes - FCCC) 18: Future Therapeutics in Metastatic RCC (Keith Flaherty - Penn) 19: Surgical Management of Metastatic RCC (Evans, Rini and Campbell) 20: Supportive Care in Metastatic RCC a: Biphosphonates (Michelson - MGH) b: Management of CNS Metastases (Hutson - Baylor) c: Palliative Care Considerations (Davis - CCF)